Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Metformin Suppresses Systemic Autoimmunity in Roquinsan/san Mice through Inhibiting B Cell Differentiation into Plasma Cells via Regulation of AMPK/mTOR/STAT3.

Lee SY, Moon SJ, Kim EK, Seo HB, Yang EJ, Son HJ, Kim JK, Min JK, Park SH, Cho ML.

J Immunol. 2017 Apr 1;198(7):2661-2670. doi: 10.4049/jimmunol.1403088. Epub 2017 Feb 27.

2.

Urinary haptoglobin, alpha-1 anti-chymotrypsin and retinol binding protein identified by proteomics as potential biomarkers for lupus nephritis.

Aggarwal A, Gupta R, Negi VS, Rajasekhar L, Misra R, Singh P, Chaturvedi V, Sinha S.

Clin Exp Immunol. 2017 May;188(2):254-262. doi: 10.1111/cei.12930. Epub 2017 Feb 23.

PMID:
28120479
3.

Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan.

Keil A, Hall SR, Körner M, Herrmann M, Schmid RA, Frese S.

Arthritis Res Ther. 2016 Oct 22;18(1):243.

4.

Insulin-Like Growth Factor Binding Protein-4 as a Marker of Chronic Lupus Nephritis.

Wu T, Xie C, Han J, Ye Y, Singh S, Zhou J, Li Y, Ding H, Li QZ, Zhou X, Putterman C, Saxena R, Mohan C.

PLoS One. 2016 Mar 28;11(3):e0151491. doi: 10.1371/journal.pone.0151491. eCollection 2016.

5.

Attribution of cause of end-stage renal disease among patients with systemic lupus erythematosus: the Georgia Lupus Registry.

Plantinga LC, Drenkard C, Pastan SO, Lim SS.

Lupus Sci Med. 2016 Jan 22;3(1):e000132. doi: 10.1136/lupus-2015-000132. eCollection 2016.

6.

Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971-2015: A Systematic Review and Bayesian Meta-Analysis.

Tektonidou MG, Dasgupta A, Ward MM.

Arthritis Rheumatol. 2016 Jun;68(6):1432-41. doi: 10.1002/art.39594.

PMID:
26815601
7.

Incidence of End-Stage Renal Disease Among Newly Diagnosed Systemic Lupus Erythematosus Patients: The Georgia Lupus Registry.

Plantinga L, Lim SS, Patzer R, McClellan W, Kramer M, Klein M, Pastan S, Gordon C, Helmick C, Drenkard C.

Arthritis Care Res (Hoboken). 2016 Mar;68(3):357-65. doi: 10.1002/acr.22685.

8.

Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials.

Corapi KM, Dooley MA, Pendergraft WF 3rd.

Arthritis Res Ther. 2015 Apr 28;17:110. doi: 10.1186/s13075-015-0621-6. Review.

9.

The cellular signature of urinary immune cells in Lupus nephritis: new insights into potential biomarkers.

Kopetschke K, Klocke J, Grießbach AS, Humrich JY, Biesen R, Dragun D, Burmester GR, Enghard P, Riemekasten G.

Arthritis Res Ther. 2015 Apr 3;17:94. doi: 10.1186/s13075-015-0600-y.

10.

Racial and Ethnic Differences in Mortality and Cardiovascular Events Among Patients With End-Stage Renal Disease Due to Lupus Nephritis.

Gómez-Puerta JA, Feldman CH, Alarcón GS, Guan H, Winkelmayer WC, Costenbader KH.

Arthritis Care Res (Hoboken). 2015 Oct;67(10):1453-62. doi: 10.1002/acr.22562.

11.

Kidney transplantation in patients with systemic lupus erythematosus.

Lionaki S, Skalioti C, Boletis JN.

World J Transplant. 2014 Sep 24;4(3):176-82. doi: 10.5500/wjt.v4.i3.176. Review.

12.

Chapter 12: Lupus nephritis.

[No authors listed]

Kidney Int Suppl (2011). 2012 Jun;2(2):221-232. No abstract available.

13.

The pathogenesis, diagnosis and treatment of lupus nephritis.

Schwartz N, Goilav B, Putterman C.

Curr Opin Rheumatol. 2014 Sep;26(5):502-9. doi: 10.1097/BOR.0000000000000089. Review.

14.

Identification of stage-specific genes associated with lupus nephritis and response to remission induction in (NZB × NZW)F1 and NZM2410 mice.

Bethunaickan R, Berthier CC, Zhang W, Eksi R, Li HD, Guan Y, Kretzler M, Davidson A.

Arthritis Rheumatol. 2014 Aug;66(8):2246-58. doi: 10.1002/art.38679.

15.

Quality of care for incident lupus nephritis among Medicaid beneficiaries in the United States.

Yazdany J, Feldman CH, Liu J, Ward MM, Fischer MA, Costenbader KH.

Arthritis Care Res (Hoboken). 2014 Apr;66(4):617-24. doi: 10.1002/acr.22182.

16.

Cgnz1 allele confers kidney resistance to damage preventing progression of immune complex-mediated acute lupus glomerulonephritis.

Ge Y, Jiang C, Sung SS, Bagavant H, Dai C, Wang H, Kannapell CC, Cathro HP, Gaskin F, Fu SM.

J Exp Med. 2013 Oct 21;210(11):2387-401. doi: 10.1084/jem.20130731. Epub 2013 Oct 7.

17.
18.

Unmet medical needs in systemic lupus erythematosus.

Lateef A, Petri M.

Arthritis Res Ther. 2012;14 Suppl 4:S4. doi: 10.1186/ar3919. Epub 2012 Dec 18. Review.

19.

Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis.

Xia Y, Campbell SR, Broder A, Herlitz L, Abadi M, Wu P, Michaelson JS, Burkly LC, Putterman C.

Clin Immunol. 2012 Nov;145(2):108-21. doi: 10.1016/j.clim.2012.08.008. Epub 2012 Aug 20.

20.

Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis.

Berthier CC, Bethunaickan R, Gonzalez-Rivera T, Nair V, Ramanujam M, Zhang W, Bottinger EP, Segerer S, Lindenmeyer M, Cohen CD, Davidson A, Kretzler M.

J Immunol. 2012 Jul 15;189(2):988-1001. doi: 10.4049/jimmunol.1103031. Epub 2012 Jun 20.

Supplemental Content

Support Center